Epidemiology Series Forecast Report on Pulmonary Hypertension in 8 Major Markets
Pulmonary Hypertension (PH) is a condition in which pulmonary arterial pressure is 25 mmHg or greater, measured via a cardiac catheterisation. There is a number of underlying causes for this syndrome and can be groups into different classifications according to the Dana Point. This report provides the current prevalent population for PH across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of PH. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team , several of the main symptoms and co-morbidities of PH have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for PH include:
• COPD
• Fibrotic Diseases
• Cardiovascular Diseases
o Valvular Dysfunction
o Congenital Heart Disease
• Diabetes
• Thyroid Disease
• Deep Vein Thrombosis (DVT) and Thrombotic Events
• Obstructive Sleep Apnoea (OSA)
• Schistosomiasis
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global PH’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of PH and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on PH’s prevalent population.
• Identify sub-populations within PH which require treatment.
• Gain an understanding of the specific markets that have the largest number of PH patients.
• Introduction
• Cause of the Disease
• Risk Factors and Prevention
• Diagnosis of the Disease
o Haemodynamic definitions of Pulmonary Hypertension
• Variation by Geography /Ethnicity
• Disease Prognosis and Clinical Course
• Key Co-Morbid Conditions / Features Associated with the Disease
• Methodology for Quantifications of Patient Number
o Additional Data Available on Request
• Top Line Prevalence for Pulmonary Hypertension
• PH by Dana Point Classification Grouping
o PH by Dana Point Grouping
• Pulmonary Arterial Hypertension
o PAH caused by Portopulmonary Hypertension
o PAH caused by Congenital Heart Disease
o PAH caused by Connective Tissue Disease
o Significant Co-morbid Conditions Associated with PAH
• Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
o CTEPH by NYHA Functional Class
o CTEPH by Operable Status
o Significant Co-morbid Conditions Associated with CTEPH
• Abbreviations and Acronyms used in the Report
• Other Black Swan Analysis Publications
• Patient Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
• Dana Point Clinical Classification of Pulmonary Hypertension
• Haemodynamic Definitions of Pulmonary Hypertension
• Functional Classification of Pulmonary Hypertension by NYHA Class
• Prevalence of PH, total (000s)
• Prevalence of PH, males (000s)
• Prevalence of PH, females (000s)
• PH by Main DANA Grouping, total (000s)
• PAH by NYUHA Class at Presentation, total (000s)
• PAH by Underlying Aetiology, total (000s)
• PAH – Severity of Right Ventricle Enlargement (000s)
• Idiopathic PAH by NYHA class, total (000s)
• Portopulmonary Hypertension by NYHDA Class, total (000s)
• PAH Caused by Congenital Heart Disease by NYHDA class, total (000s)
• PAH Caused by Connective Tissue Disease by NYHDA class, total (000s)
• Prevalence of Hypertension in Patients with PAH, total (000s)
• Prevalence of Diabetes in Patients with PAH, total (000s)
• Prevalence of Ischemic Heart Disease in Patients with PAH, total (000s)
• Prevalence of Thyroid Disease in Patients with PAH, total (000s)
• Prevalence of Obstructive Sleep Apnoea in Patients with PAH, total (000s)
• Prevalence of Obstructive Airway Disease in Patients with PAH, total (000s)
• CTEPH by NYHA class, total (000s)
• CTEPH Patients by Operable Status, total (000s)
• Prevalence of COPD in Patients with CTEPH, total (000s)
• Prevalence of Thrombophilic Disorder in Patients with CTEPH, total(000s)
• Prevalence of Varicose Veins in Patients with CTEPH, total (000s)
• Prevalence of Confirmed Previous Acute PE in Patients with CTEPH, total (000s)
• Abbreviations and Acronyms used in the Report
• USA Prevalence of PH by 5-yr age cohort, males (000s)
• USA Prevalence of PH by 5-yr age cohort, females (000s)
• France Prevalence of PH by 5-yr age cohort, males (000s)
• France Prevalence of PH by 5-yr age cohort, females (000s)
• Germany Prevalence of PH by 5-yr age cohort, males (000s)
• Germany Prevalence of PH by 5-yr age cohort, females (000s)
• Italy Prevalence of PH by 5-yr age cohort, males (000s)
• Italy Prevalence of PH by 5-yr age cohort, females (000s)
• Spain Prevalence of PH by 5-yr age cohort, males (000s)
• Spain Prevalence of PH by 5-yr age cohort, females (000s)
• United Kingdom Prevalence of PH by 5-yr age cohort, males (000s)
• United Kingdom Prevalence of PH by 5-yr age cohort, females (000s)
• Brazil Prevalence of PH by 5-yr age cohort, males (000s)
• Brazil Prevalence of PH by 5-yr age cohort, females (000s)
• Japan Prevalence of PH by 5-yr age cohort, males (000s)
• Japan Prevalence of PH by 5-yr age cohort, females (000s)
+1 888 709 8757
Chat With Us